These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 25181339)
61. Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Itatsu K; Zen Y; Yamaguchi J; Ohira S; Ishikawa A; Ikeda H; Sato Y; Harada K; Sasaki M; Sasaki M; Sakamoto H; Nagino M; Nimura Y; Ohta T; Nakanuma Y Hum Pathol; 2008 May; 39(5):710-9. PubMed ID: 18329694 [TBL] [Abstract][Full Text] [Related]
62. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129 [TBL] [Abstract][Full Text] [Related]
63. Long non-coding RNA HOTAIR promotes tumorigenesis and forecasts a poor prognosis in cholangiocarcinoma. Qin W; Kang P; Xu Y; Leng K; Li Z; Huang L; Gao J; Cui Y; Zhong X Sci Rep; 2018 Aug; 8(1):12176. PubMed ID: 30111807 [TBL] [Abstract][Full Text] [Related]
64. YAP is a critical oncogene in human cholangiocarcinoma. Pei T; Li Y; Wang J; Wang H; Liang Y; Shi H; Sun B; Yin D; Sun J; Song R; Pan S; Sun Y; Jiang H; Zheng T; Liu L Oncotarget; 2015 Jul; 6(19):17206-20. PubMed ID: 26015398 [TBL] [Abstract][Full Text] [Related]
65. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis. Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031 [TBL] [Abstract][Full Text] [Related]
66. Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma. Li Y; He D; Lu ZJ; Gu XF; Liu XY; Chen M; Tu YX; Zhou Y; Owen G; Zhang X; Jiang D BMC Cancer; 2024 Oct; 24(1):1232. PubMed ID: 39375615 [TBL] [Abstract][Full Text] [Related]
67. Cul4B is a novel prognostic marker in cholangiocarcinoma. Li P; Zhang L; Yang M; Qi M; Jin X; Han B Oncol Lett; 2017 Aug; 14(2):1265-1274. PubMed ID: 28808481 [TBL] [Abstract][Full Text] [Related]
68. BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner. Liu Z; Hu C; Zheng L; Liu J; Li K; Li X; Wang Y; Mu W; Chen T; Shi A; Qiu B; Zhang X; Zhang Z; Xu Y Cell Mol Life Sci; 2022 Aug; 79(9):469. PubMed ID: 35932322 [TBL] [Abstract][Full Text] [Related]
69. Expression of Smad7 in cholangiocarcinoma: prognostic significance and implications for tumor metastasis. Huang Q; Liu L; Liu CH; Shao F; Xie F; Zhang CH; Hu SY Asian Pac J Cancer Prev; 2012; 13(10):5161-5. PubMed ID: 23244128 [TBL] [Abstract][Full Text] [Related]
70. 67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma. Xu J; Li D; Li X; Liu Z; Li T; Jiang P; He Q; Tian F; Gao Y; Wang D; Wang S Dig Liver Dis; 2014 Aug; 46(8):750-7. PubMed ID: 24794791 [TBL] [Abstract][Full Text] [Related]
72. BMP-7 blocks the effects of TGF-β-induced EMT in cholangiocarcinoma. Duangkumpha K; Techasen A; Loilome W; Namwat N; Thanan R; Khuntikeo N; Yongvanit P Tumour Biol; 2014 Oct; 35(10):9667-76. PubMed ID: 24969562 [TBL] [Abstract][Full Text] [Related]
73. HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. Lee HJ; Chung JY; Hewitt SM; Yu E; Hong SM Virchows Arch; 2012 Nov; 461(5):521-30. PubMed ID: 23052372 [TBL] [Abstract][Full Text] [Related]
74. Overexpression of SOX4 promotes cell migration and invasion of renal cell carcinoma by inducing epithelial-mesenchymal transition. Ruan H; Yang H; Wei H; Xiao W; Lou N; Qiu B; Xu G; Song Z; Xiao H; Liu L; Zhou Y; Hu W; Chen K; Chen X; Zhang X Int J Oncol; 2017 Jul; 51(1):336-346. PubMed ID: 28534986 [TBL] [Abstract][Full Text] [Related]
75. A novel three‑miRNA signature predicts survival in cholangiocarcinoma based on RNA‑Seq data. Cao J; Sun L; Li J; Zhou C; Cheng L; Chen K; Yan B; Qian W; Ma Q; Duan W Oncol Rep; 2018 Sep; 40(3):1422-1434. PubMed ID: 29956786 [TBL] [Abstract][Full Text] [Related]
76. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. Borad MJ; Gores GJ; Roberts LR Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789 [TBL] [Abstract][Full Text] [Related]
77. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway. Sun R; Liu Z; Qiu B; Chen T; Li Z; Zhang X; Xu Y; Zhang Z EBioMedicine; 2019 Sep; 47():142-155. PubMed ID: 31492557 [TBL] [Abstract][Full Text] [Related]
78. Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival. Gomes RV; Rodrigues MÂ; Rodrigues JBSR; Vidigal PT; Damasceno KA; Lima HA; Gomes DA; Machado CJ; Resende V Rev Col Bras Cir; 2018 Jul; 45(3):e1826. PubMed ID: 29995151 [TBL] [Abstract][Full Text] [Related]
79. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Shibahara H; Tamada S; Higashi M; Goto M; Batra SK; Hollingsworth MA; Imai K; Yonezawa S Hepatology; 2004 Jan; 39(1):220-9. PubMed ID: 14752841 [TBL] [Abstract][Full Text] [Related]
80. Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma. Li Q; Wang JM; Liu C; Xiao BL; Lu JX; Zou SQ Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):70-5. PubMed ID: 18234642 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]